Observational study

| Ciencia | Creatividad | Innovación | Ciencia | Creatividad | Innovación | Ciencia | Creatividad | Innovación | Ciencia | Creatividad | Innovación | Ciencia | Creatividad | Innovación | Ciencia | Creatividad | Innovación

Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study

Elsevier Publication Efficacy Observational Study for eslicarbazepine

Eslicarbazepine acetate (ESL, Aptiom™) is a once-daily anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS).

Prospective, non-interventional study recruited of partial-onset seizures (POS) patients in 17 hospitals in Spain. It aims at supporting previous findings in ESL effectiveness and tolerability as monotherapy for patients with POS. It also supported early use due to its frequent use as monotherapy and lack of severe side effects.

Más Casos de éxito